Global Impact of COVID-19 pandemic on Gastric Cancer Treatment: findings from a global cross-sectional multicentre study (GLEOHUG-GC).

s European Journal of Surgical Oncology 48 (2022) e45ee55 vs 0 in TTE group (p<0.01). 3-year overall survival was comparable, being 36.5% after TEG and 48.4% after TTE (p1⁄40.12). After TEG, we reported a higher rate of locoregional recurrence (16.7% vs 5.1% after TTE, p1⁄40.04). At multivariate analysis, (y)pTcategory was an independent risk factor for 3year recurrence. After matching, TEGwas still associated with an increased risk of incomplete tumor resection (p1⁄40.03) and proximal margin involvement (p<0.01), while there were no more differences in postoperative morbidity (p1⁄40.56) and mortality (p1⁄40.31) between the groups. Conclusions: Siewert type II tumors can be treated with transhiatal extended gastrectomy or transthoracic esophagectomy, provided that an appropriate patient selection is performed. Even so, TEG exposes the patient to an increased risk of an irradical resection at the proximal margin.